CDMO News
Boehringer Ingelheim Expands Contract Manufacturing in China with Regulatory Reform
Boehringer Ingelheim BioXcellence™ has secured approval to participate in China’s segmented manufacturing reform, a regulatory initiative led by the National Medical Products Administration (NMPA). This programme aims to enhance efficiency and flexibility in the production of biological products. With this qualification,
10 March 2025